| http://www.w3.org/ns/prov#value | - beta-lactam/aminoglycoside combination therapy usually outweighs any potential benefit (level I evidence).10,11 Therefore, monotherapy regimens are preferred in most circumstances, particularly in elderly patients, and in patients with, or at high risk of, renal impairment.The choice of piperacillin-tazobactam or cefepime as the institutional first-line monotherapy for neutropenic fever must be s
|
